Chemical Compound Review:
Risperidal 3-[2-[4-(6- fluorobenzo[d]isoxazol-3-yl)- 1...
Synonyms:
risperidone, R-64766, R-64,766, R64766, R 64766, ...
Lang,
Ulmschneider,
Koenig,
Rui,
Mahmoud,
Price,
Thase,
Zhang,
Miyahara,
Labelle,
Kim,
Scheppach,
Eriksson,
Allison,
Zhou,
Keith Karcher,
Brandstätter,
Miklowitz,
Scordo,
Holmes,
Pantelis,
Labelle,
McCracken,
Tollefson,
Perucca,
Vandorpe,
Sokullu,
Carlson,
Shen,
Barton,
Vitiello,
Kapur,
Bergman,
Robinson,
McDougle,
McDougle,
Kabir,
Richey,
Kane,
Möller,
Ghuman,
Shammi,
Dineen,
Remington,
Akbar Khan,
Mann,
Goldman,
Sevy,
Aman,
Smith,
Pan,
Ali,
Halldin,
Honer,
Kujawa,
Pelton,
McGough,
Chuang,
Stock,
Ritz,
Addington,
Purdon,
Bauer,
Arnold,
Ader,
David,
Davies,
Mamo,
Tierney,
Susce,
Goff,
Oxenstierna,
Goghari,
Fairchild,
Marangell,
Marder,
Catalano,
Gonzalez,
Avenoso,
Calabrese,
Hollway,
Cohen,
Hucking,
Stip,
Swiezy,
Nyberg,
Ostacher,
Carson,
Wu,
Nicholas A. Keks,
Zhang,
Hayden,
Martin,
Morrison,
Farde,
Ionut,
Henderson,
Evins,
Ekholm,
Malhotra,
Weber,
Müller,
Daley,
Kopala,
Koch,
Wisniewski,
Posey,
Saha,
Lencz,
Krampe,
Lapointe,
Ancione,
Anderson,
Reiss,
Copeland,
Borba,
Stringfellow,
Engel,
Potkin,
Benattia,
Schwarz,
Breier,
Chadi A. Calarge,
Vicki L. Ellingrod,
Laura Acion,
Del D. Miller,
Jessica Moline,
Michael J. Tansey,
Janet A. Schlechte,
Addington,
Romano,
Gunduz-Bruce,
Ketter,
Woerner,
Cao,
Cagliero,
Spina,
Scahill,
Michael Ingham,
Cottingham,
Riedel,
Xu,
Gatti,
Ingenito,
Jones,
Mannaert,
Shah,
de Leon,
Csernansky,
Nierenberg,
Sachs,
Schoenfeld,
Brenner,
Wedlund,
Madia,
- Risperidone and neuroleptic malignant syndrome. Tarsy, D. JAMA (1996)
- Risperidone in Parkinson's disease. Ford, B., Lynch, T., Greene, P. Lancet (1994)
- Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., Marder, S.R. Arch. Gen. Psychiatry (2003)
- Tardive dyskinesia with risperidone and anticholinergics. Suzuki, E., Obata, M., Yoshida, Y., Miyaoka, H. The American journal of psychiatry. (2002)
- Risperidone-induced hyperprolactinemia in an elderly woman. Bai, Y.M., Ciu, H.J., Guo, Z.Z. The American journal of psychiatry. (2002)
- A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. Csernansky, J.G., Mahmoud, R., Brenner, R. N. Engl. J. Med. (2002)
- Neuroleptic sensitivity to risperidone in Lewy body dementia. McKeith, I.G., Ballard, C.G., Harrison, R.W. Lancet (1995)
- Risperidone for Tourette's syndrome. Stamenkovic, M., Aschauer, H., Kasper, S. Lancet (1994)
- A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. McDougle, C.J., Holmes, J.P., Carlson, D.C., Pelton, G.H., Cohen, D.J., Price, L.H. Arch. Gen. Psychiatry (1998)
- Risperidone-induced tardive dystonia and psychosis. Vercueil, L., Foucher, J. Lancet (1999)
- Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Henderson, D.C., Cagliero, E., Copeland, P.M., Borba, C.P., Evins, E., Hayden, D., Weber, M.T., Anderson, E.J., Allison, D.B., Daley, T.B., Schoenfeld, D., Goff, D.C. Arch. Gen. Psychiatry (2005)
- Metformin for weight loss in pediatric patients taking psychotropic drugs. Morrison, J.A., Cottingham, E.M., Barton, B.A. The American journal of psychiatry. (2002)
- Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Nierenberg, A.A., Ostacher, M.J., Calabrese, J.R., Ketter, T.A., Marangell, L.B., Miklowitz, D.J., Miyahara, S., Bauer, M.S., Thase, M.E., Wisniewski, S.R., Sachs, G.S. The American journal of psychiatry. (2006)
- Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R.R., Möller, H.J., Schwarz, M.J. The American journal of psychiatry. (2002)
- Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington, D.E., Pantelis, C., Dineen, M., Benattia, I., Romano, S.J. The Journal of clinical psychiatry. (2004)
- Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. Spina, E., Avenoso, A., Scordo, M.G., Ancione, M., Madia, A., Gatti, G., Perucca, E. Journal of clinical psychopharmacology. (2002)
- Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Ader, M., Kim, S.P., Catalano, K.J., Ionut, V., Hucking, K., Richey, J.M., Kabir, M., Bergman, R.N. Diabetes (2005)
- Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E., Davies, M., Arnold, L.E., Posey, D.J., Martin, A., Ghuman, J.K., Shah, B., Chuang, S.Z., Swiezy, N.B., Gonzalez, N.M., Hollway, J., Koenig, K., McGough, J.J., Ritz, L., Vitiello, B. The American journal of psychiatry. (2005)
- Growth and sexual maturation during long-term treatment with risperidone. Dunbar, F., Kusumakar, V., Daneman, D., Schulz, M. The American journal of psychiatry. (2004)
- Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Abraham, G., Paing, W.W., Kaminski, J., Joseph, A., Kohegyi, E., Josiassen, R.C. The American journal of psychiatry. (2003)
- DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Lencz, T., Robinson, D.G., Xu, K., Ekholm, J., Sevy, S., Gunduz-Bruce, H., Woerner, M.G., Kane, J.M., Goldman, D., Malhotra, A.K. The American journal of psychiatry. (2006)
- Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Honey, G.D., Bullmore, E.T., Soni, W., Varatheesan, M., Williams, S.C., Sharma, T. Proc. Natl. Acad. Sci. U.S.A. (1999)
- An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Lang, D.J., Kopala, L.C., Vandorpe, R.A., Rui, Q., Smith, G.N., Goghari, V.M., Honer, W.G. The American journal of psychiatry. (2001)
- Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Lang, D.J., Kopala, L.C., Vandorpe, R.A., Rui, Q., Smith, G.N., Goghari, V.M., Lapointe, J.S., Honer, W.G. The American journal of psychiatry. (2004)
- The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. Ruiu, S., Marchese, G., Saba, P.L., Gessa, G.L., Pani, L. Mol. Psychiatry (2000)
- Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Liddle, P.F., Lane, C.J., Ngan, E.T. The British journal of psychiatry : the journal of mental science. (2000)
- Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Nyberg, S., Eriksson, B., Oxenstierna, G., Halldin, C., Farde, L. The American journal of psychiatry. (1999)
- Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Rammes, G., Eisensamer, B., Ferrari, U., Shapa, M., Gimpl, G., Gilling, K., Parsons, C., Riering, K., Hapfelmeier, G., Bondy, B., Zieglgänsberger, W., Holsboer, F., Rupprecht, R. Mol. Psychiatry (2004)
- Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Knegtering, R., Baselmans, P., Castelein, S., Bosker, F., Bruggeman, R., van den Bosch, R.J. The American journal of psychiatry. (2005)
- Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Keks, N.A., Ingham, M., Khan, A., Karcher, K. Br. J. Psychiatry (2007)
- A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. Bork, J.A., Rogers, T., Wedlund, P.J., de Leon, J. The Journal of clinical psychiatry. (1999)
- Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. Zhang, X.Y., Zhou, D.F., Cao, L.Y., Zhang, P.Y., Wu, G.Y., Shen, Y.C. The Journal of clinical psychiatry. (2004)
- The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. de Leon, J., Susce, M.T., Pan, R.M., Fairchild, M., Koch, W.H., Wedlund, P.J. The Journal of clinical psychiatry. (2005)
- Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Calarge, C.A., Ellingrod, V.L., Acion, L., Miller, D.D., Moline, J., Tansey, M.J., Schlechte, J.A. Pharmacogenet. Genomics (2009)
- Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Purdon, S.E., Jones, B.D., Stip, E., Labelle, A., Addington, D., David, S.R., Breier, A., Tollefson, G.D. Arch. Gen. Psychiatry (2000)
- A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Remington, G., Mamo, D., Labelle, A., Reiss, J., Shammi, C., Mannaert, E., Mann, S., Kapur, S. The American journal of psychiatry. (2006)